Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (Treating to New Targets) study

被引:75
作者
Waters, David D.
LaRosa, John C.
Barter, Philip
Fruchart, Jean-Charles
Gotto, Antonio M., Jr.
Carter, Roddy
Breazna, Andrei
Kastelein, John J. P.
Grundy, Scott M.
机构
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] SUNY, Hlth Sci Ctr, New York, NY USA
[3] Heart Res Inst, Sydney, NSW, Australia
[4] Inst Pasteur, F-59019 Lille, France
[5] Cornell Univ, Weil Med Coll, New York, NY USA
[6] Univ Amsterdam, Acad Med Ctr, NL-1012 WX Amsterdam, Netherlands
[7] Univ Texas, SW Med Ctr, Dallas, TX 75230 USA
关键词
D O I
10.1016/j.jacc.2006.07.041
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE We sought to assess the effects on cerebrovascular events of treating patients with stable coronary disease with low-density lipoprotein cholesterol (LDL-C) levels substantially below 100 mg/dl. BACKGROUND Lowering LDL-C with statins has been shown to reduce the risk of stroke in patients with stable coronary disease. In observational studies, naturally low cholesterol levels have been associated with an increased risk of hemorrhagic stroke. The cerebrovascular benefits of treating patients with stable coronary disease to LDL-C levels substantially below 100 mg/dl have not been previously investigated. METHODS. We describe an analysis of cerebrovascular events in the Treating to New Targets study, a trial where 10,001 patients with documented coronary disease were randomized to treatment with atorvastatin at 10 mg/day or 80 mg/day and followed for a median of 4.9 years. RESULTS Mean LDL-C levels were 101 mg/dl on 10 mg atorvastatin and 77 mg/dl on 80 mg. In addition to the reduction in major cardiovascular events (hazard ratio 0.78, 95% confidence interval [CI] 0.69 to 0.89; p = 0.0002), the primary end point of the trial, patients in the 80-mg arm experienced a reduction in cerebrovascular events (hazard ratio 0.77, 95% CI 0.64 to 0.93; p = 0.007) and stroke (hazard ratio 0.75, 95% CI 0.59 to 0.96; p = 0.02). Each 1-mg/dl reduction in LDL-C with treatment was associated with a 0.6% relative risk reduction in cerebrovascular events (p = 0.002) and a 0.5% relative risk reduction in stroke (p = 0.041). The incidence of hemorrhagic stroke was similar in the 80-mg and 10-mg groups, 16 and 18 respectively, and the hemorrhagic strokes were distributed evenly across quintiles of achieved LDL-C during treatment. CONCLUSIONS Among patients with established coronary disease, treating to an LDL-cholesterol substantially below 100 mg/dl with 80 mg/day atorvastatin reduces both stroke and cerebrovascular events by an additional 20% to 25% compared with the 10 mg/day dose. An increase in hemorrhagic stroke was not seen at low LDL-C levels.
引用
收藏
页码:1793 / 1799
页数:7
相关论文
共 28 条
  • [1] Amarenco P, 2006, NEW ENGL J MED, V355, P549
  • [2] [Anonymous], 1991, JAMA, V265, P3255
  • [3] CHOLESTEROL REDUCTION AND THE RISK FOR STROKE IN MEN - A METAANALYSIS OF RANDOMIZED, CONTROLLED TRIALS
    ATKINS, D
    PSATY, BM
    KOEPSELL, TD
    LONGSTRETH, WT
    LARSON, EB
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (02) : 136 - 145
  • [4] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    Baigent, C
    Keech, A
    Kearney, PM
    Blackwell, L
    Buck, G
    Pollicino, C
    Kirby, A
    Sourjina, T
    Peto, R
    Collins, R
    Simes, J
    [J]. LANCET, 2005, 366 (9493) : 1267 - 1278
  • [5] ELEVATED SERUM-CHOLESTEROL IS A RISK FACTOR FOR BOTH CORONARY HEART-DISEASE AND THROMBOEMBOLIC STROKE IN HAWAIIAN JAPANESE MEN - IMPLICATIONS OF SHARED RISK
    BENFANTE, R
    YANO, K
    HWANG, LJ
    CURB, JD
    KAGAN, A
    ROSS, W
    [J]. STROKE, 1994, 25 (04) : 814 - 820
  • [6] Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    Colhoun, HM
    Betteridge, DJ
    Durrington, PN
    Hitman, GA
    Neil, HAW
    Livingstone, SJ
    Thomason, MJ
    Mackness, MI
    Charlton-Menys, V
    Fuller, JH
    [J]. LANCET, 2004, 364 (9435) : 685 - 696
  • [7] Collins R, 2004, LANCET, V363, P757
  • [8] Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques - Implications for plaque stabilization
    Crisby, M
    Nordin-Fredriksson, G
    Shah, PK
    Yano, J
    Zhu, J
    Nilsson, J
    [J]. CIRCULATION, 2001, 103 (07) : 926 - 933
  • [9] Statins and stroke: evidence for cholesterol-independent effects
    Di Napoli, R
    Taccardi, AA
    Oliver, M
    De Caterina, R
    [J]. EUROPEAN HEART JOURNAL, 2002, 23 (24) : 1908 - 1921
  • [10] EFFECT OF LOVASTATIN ON EARLY CAROTID ATHEROSCLEROSIS AND CARDIOVASCULAR EVENTS
    FURBERG, CD
    ADAMS, HP
    APPLEGATE, WB
    BYINGTON, RP
    ESPELAND, MA
    HARTWELL, T
    HUNNINGHAKE, DB
    LEFKOWITZ, DS
    PROBSTFIELD, J
    RILEY, WA
    YOUNG, B
    [J]. CIRCULATION, 1994, 90 (04) : 1679 - 1687